## NANOPHASE TECHNOLOGIES CORPORATION

## CONSOLIDATED BALANCE SHEETS

(Unaudited Consolidated Condensed)

(in thousands except share and per share

	data)						
ASSETS		June 2024 naudited)	December 31, 2023				
Current assets:							
Cash	\$	2,358	\$	1,722			
Trade accounts receivable, less allowance for credit losses of \$307	Ψ	2,330	Ψ	1,722			
for June 30, 2024 and \$225 for December 31, 2023		5,932		3,467			
Inventories, net		13,874		10,031			
Prepaid expenses and other current assets		2,096		1,082			
Total current assets		24,260		16,302			
Total valient assets		2 1,200		10,502			
Equipment and leasehold improvements, net		9,261		8,668			
Operating leases, right of use		7,326		7,907			
Other assets, net		2		4			
	\$	40,849	\$	32,881			
LIABILITIES AND STOCKHOLDERS' EQUITY							
Current liabilities:							
Lines of credit - accounts receivable, related party		2,272		2,810			
Current portion of long term debt, related party		· -		2,000			
Current portion of operating lease obligations		1,043		1,297			
Accounts payable		5,577		6,260			
Current portion of deferred revenue		3,077		2,353			
Accrued expenses		1,800		869			
Total current liabilities		13,769		15,589			
Long-term portion of operating lease obligations		8,714		9,152			
Long-term debt - inventory, related party		5,200		5,000			
Long-term debt, related party		1,000		1,000			
Asset retirement obligation		242		238			
Total long-term liabilities		15,156		15,390			
Shareholders' equity:							
Preferred stock, \$.01 par value, 24,088 shares authorized and							
no shares issued and outstanding		_		_			
Common stock, \$.01 par value, 95,000,000 and 60,000,000 shares authorized;							
69,860,984 and 49,627,254 shares issued and outstanding on June 30, 2024							
and December 31, 2023, respectively		698		496			
Additional paid-in capital		114,140		106,069			
Accumulated deficit		(102,914)		(104,663)			
Total stockholders' equity		11,924		1,902			
Total liabilities and shareholders' equity	\$	40,849	\$	32,881			
• •				<u> </u>			

### NANOPHASE TECHNOLOGIES CORPORATION

## CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed)

(in thousands except share and per share data)

	Three months ended June 30,			Six months ended June 30,				
		2024		2023		2024		2023
Revenue:	-			<u> </u>				
Product revenue	\$	12,923	\$	11,844	\$	22,694	\$	21,180
Other revenue		123		28		220		149
Net revenue		13,046		11,872		22,914		21,329
Cost of revenue		9,306		8,197		15,594		15,505
Gross profit		3,740		3,675		7,320		5,824
Operating expense:								
Research and development expense		864		991		1,776		1,994
Selling, general and administrative expense		1,829		2,105		3,388		4,255
Income from operations		1,047		579		2,156		(425)
Interest expense		191		246		409		400
Other income, net				-		-		
Income before provision for income taxes		856		333		1,747		(825)
Provision for income taxes		-		-		-		-
Net income (loss)	\$	856	\$	333	\$	1,747	\$	(825)
Net income (loss) per share-basic	\$	0.02	\$	0.01	\$	0.03	\$	(0.02)
Weighted average number of common shares outstanding - basic		56,674,170		49,567,338		54,675,011		49,498,755
Net income per share-diluted	\$	0.01	\$	0.01	\$	0.03	\$	(0.02)
Weighted average number of common shares outstanding - diluted		58,709,170		50,136,338		56,662,011		49,498,755

#### NANOPHASE TECHNOLOGIES CORPORATION

# CONSOLIDATED STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE (Unaudited Consolidated Condensed)

(in thousands except share and per share data)

	Three months ended June 30,			Six months ended June 30,				
		2024		2023		2024	,	2023
Revenue:								
Product revenue	\$	12,923	\$	11,844	\$	22,694	\$	21,180
Other revenue		123		28		220		149
Net revenue		13,046		11,872		22,914		21,329
Operating expense:								
Cost of revenue detail:								
Depreciation		222		158		444		316
Non-Cash equity compensation		28		28		54		55
Other costs of revenue		9,056		8,011		15,096		15,134
Cost of revenue	-	9,306		8,197		15,594		15,505
Gross profit		3,740		3,675		7,320		5,824
Research and development expense detail:								
Depreciation		5		7		11		14
Non-Cash equity compensation		32		45		65		92
Other research and development expense		827		939		1,700		1,888
Research and development expense		864		991		1,776	· ·	1,994
Selling, general and administrative expense detail:								
Depreciation and amortization		7		8		14		15
Non-Cash equity compensation		97		123		198		258
Other selling, general and administrative expense		1,725		1,974		3,176		3,982
Selling, general and administrative expense		1,829		2,105		3,388		4,255
Income from operations	·	1,047		579		2,156		(425)
Interest expense		191		246		409		400
Other income, net								
Income before provision for income taxes		856		333		1,747		(825)
Provision for income taxes		-		-		-		-
Net (loss) income	\$	856	\$	333	\$	1,747	\$	(825)
Non-GAAP Disclosure (see note regarding Non-GAAP disclosures):								
Addback Interest, net		191		246		409		116
Addback Depreciation/Amortization		234		134		469		269
Addback Non-Cash Equity Compensation		157		135		317		302
Subtract Non-Cash Other Income		-		-	-	-		-
Adjusted EBITDA	\$	1,438	\$	848	\$	2,942	\$	(138)